Resveratrol is Not Anti-Aging. It May Have Benefits for Type 2 Diabetes

by Nils Osmar – March 2026

The information in this article is not intended as, and should not be taken as, medical advice. Interventions like exercising, dietary changes, and taking medications and supplements can have both benefits and side effects, Please consult with a medical professional about any medical concerns. See full Medical Disclaimer

Resveratrol is a naturally occurring polyphenol found in grape skins, red wine, blueberries, peanuts, and some other plants. It functions in plants as a kind of stress response compound, produced when the plant is under attack by pathogens. There has been speculation that it might have anti-aging properties, and there have been claims that it could in theory extend lifespan by activating sirtuin genes. Some have also pointed out possible anti-cancer benefits.

Do these claims and speculations hold up to scrutiny?

Anti-aging claims

The anti-aging story began in 2003 when David Sinclair’s lab at Harvard reported that resveratrol dramatically extended yeast lifespan, apparently by activating sirtuin proteins (specifically Sir2/SIRT1). Resveratrol was reported to stimulate SIRT1, increase DNA stability, and extend yeast lifespan by 70%, with subsequent studies in worms and fruit flies confirming that resveratrol activates sirtuins. Source: Frontiersin

During this period, a number of magazines ran articles touting resveratrol’s supposed anti-aging characteristics.

Interest increased when it was shown to improve health and survival of flies and mice on a high-calorie diet, and in mice, it improved adipose insulin signaling. Source: Frontiersin

However, the translation to humans has been disappointing. Subsequent studies, including those using advanced technologies like CRISPR, showed that resveratrol does not directly activate sirtuins and might induce cellular stress instead. Source: Healthspan The mouse studies which had shown benefits also came under question, when it was clarified that the mice had been eating a diet extremely high in unhealthy fats.

Attempts by pharmaceutical companies to enhance resveratrol’s effectiveness through derivatives or mimetics designed to better activate sirtuin pathways have not resulted in significant improvements in healthspan or lifespan. Source: Healthspan

ITP Studies

The Interventional Testing Program (ITP), which rigorously tests longevity compounds in mice across multiple research sites, has identified several reliable longevity-enhancing agents, such as rapamycin and acarbose, which have shown consistent results across various models.

The ITP has tested resveratrol, but has not found signficant life extension benefits in animals given it. Source: Healthspan

The sirtuin activation controversy

David Sinclair has spent years promoting the theory that resveratrol has benefits related to activating sirtuin genes, in particular SIRT1 activator, which he has represented as being life extending.

Other researchers have raised concerns about these statements. Resveratrol has been shown to activate SIRT1 in yeast, but some dispute the claim that it does so in humans.

And even it it were proven to, there is no strong evidence that the SIRT1 gene is life extending. A different sirtuin gene (SIRT6) does appear to have life extending properties.

Human clinical trials

Life extension can’t be tested directly in humans. But it is possible to test compounds to verify whether they have health banefits. Almost 200 clinical studies over the last 20 years have evaluated the safety and effects of resveratrol in humans. Some suggest there may be benefits.

The areas with positive signals include: improved glucose metabolism and cardiovascular disease markers, reduction in oxidative stress and inflammation, neuroprotective effects, antidiabetic properties. There has also been some evidence of delayed cognitive decline in Alzheimer’s disease patients. Source: Frontiers

Some clinical trials have shown promising results when using resveratrol to treat type 2 diabetes and metabolic syndrome. But it has not yet been approved medically for either condition.

One concern that is often raised in regard to human trials is that resveratrol has low bioavailability in humans and thus low clinical potency. Source: Frontiers It is metabolized and excreted rapidly, meaning that the concentrations achieved in human tissues are typically far lower than those used in cell and animal studies. This makes it difficult to extrapolate meaningfully from animals to humans.

What about cancer?

The evidence is weak and inconsistent on this question. Concerns have been raised that under some conditions resveratrol may even be pro-cancer.

Evidence of anti-cancer benefits:

Preclinical data has shown resveratrol inducing apoptosis and inhibiting cancer cell proliferation across many cell types.
For example, resveratrol has been shown to inhibit cancer cell proliferation via apoptosis,
Trans-resveratrol appears to decrease methylation of the tumor suppressor gene RASSF-1α in women at increased risk of breast cancer. Source: Memorial Sloan Kettering Cancer Center
Some epidemiological data suggested dietary resveratrol was inversely associated with breast cancer risk.

In cell culture and animal models, the evidence for resveratrol’s anti-cancer properties is extensive. Resveratrol has been shown to interfere with all three stages of carcinogenesis (initiation, promotion, and progression), and it modulates multiple molecular targets relevant to cancer, including pathways involved in inflammation, oxidative stress, and programmed cell death.

However, the translation to human clinical evidence has been problematic. Despite thousands of published preclinical studies on resveratrol and cancer, the number of actual human clinical trials remains very small, and many of those focused primarily on safety and pharmacokinetics rather than efficacy.

The few human cancer trials that have been conducted are small and largely inconclusive. Some modest positive signals have emerged: one trial in colorectal cancer patients found that resveratrol supplementation increased markers of cancer cell death in tumor tissue. Another showed that resveratrol modulated enzymes involved in carcinogen activation and detoxification. But patient sample sizes in these studies were tiny — often fewer than ten cancer patients — making it impossible to draw firm conclusions.

Could Resveratrol be Pro-Cancer?

Some have raised this concern.

The problem is that resveratrol has estrogen-like properties and can activate both estrogen and androgen receptors, which raises theoretical concerns about stimulating the growth of hormone-sensitive cancers. And a trial of high-dose micronized resveratrol in multiple myeloma patients had to be halted after serious adverse events, including kidney failure. As a phytoestrogen, resveratrol possesses both estrogenic and anti-estrogenic activities on ERα-positive breast cancer. Source: PubMed Central

One study using a mouse model found that instead of inhibiting tumor growth, resveratrol shortened tumor latency and enhanced tumor multiplicity — a genuinely alarming finding.

Resveratrol exhibits estrogen-like properties and activates transcription by both estrogen and androgen receptors, which can lead to the stimulation of cancer cell proliferation. This in theory could lead to stimulation of cancer cell proliferation. Source: Memorial Sloan Kettering Cancer Center

Complicating the evidence, this effect may be dose-dependent and cell-type specific. Some studies raise concerns about a possible increased risk of breast cancer progression in those consuming high-dose resveratrol supplements, Source: PubMed Central

Another Troubling Finding

One study suggested that resveratrol might help reduce prostate tumorigenesis through reduced prostatic levels of mTOR complex 1 activity and increased expression of SIRT1. Source: Memorial Sloan Kettering Cancer Center But even in prostate cancer, it also increases angiogenesis and inhibits apoptosis in vivo — again, a mixed signal. This mixed message is a key example of why “it works in a petri dish” is not a reliable guide to supplementation decisions. Both human and animal studies are also needed.

That’s not just a null result — it’s a reversal. In the dish, resveratrol inhibits prostate cancer cell growth. In the living animal, it increases blood vessel formation to the tumor and reduces programmed cell death. It’s a key reason that people with cancer of any kind should not assume one study is sufficient, or do self-treatment.

A high-dose micronized resveratrol trial in which resveratrol was used in the treatment of multiple myeloma was stopped due to serious adverse events including renal failure.

The bottom line for cancer: The preclinical evidence is genuinely promising and worth continued investigation. But human clinical evidence for cancer prevention or treatment remains preliminary and insufficient to recommend resveratrol for this purpose.

Type 2 Diabetes

I mentioned type 2 diabetes above. I go into it more here.

Several randomized, controlled trials have shown that resveratrol, even at low doses, can improve insulin sensitivity, reduce blood glucose levels, and delay post-meal glucose spikes in people with type 2 diabetes. Some evidence suggests it may enhance the effects of metformin, the most widely prescribed diabetes medication. A meta-analysis also found that resveratrol supplementation significantly reduced both systolic and diastolic blood pressure, though results across individual trials have been inconsistent.

Some clinical evidence also points to modest benefits for endothelial function (the health of blood vessel linings) and improvements in certain inflammatory markers. A 24-month randomized crossover trial in postmenopausal women found improvements in pain perception, menopausal symptoms, and overall well-being. A 2025 trial found some benefits for skin aging from topical application.

However, these findings come with important caveats. Results across trials are inconsistent and often dose-dependent in unpredictable ways. Some studies using higher doses showed no benefit, while some using lower doses did — the opposite of what you would typically expect. A 2024 review noted that the clinical findings on cardiovascular outcomes are difficult to interpret because the effects are inconsistent and unrelated to dose in any clear pattern.

Improving biomarkers is also not the same as improving clinical outcomes. Showing that resveratrol can nudge a lab value in a favorable direction does not necessarily mean it prevents heart attacks or extends healthy years. Larger, longer trials are needed to determine that.

Safety profile

At moderate doses (up to 1g/day), resveratrol appears generally well-tolerated. At higher doses (2.5–5g/day), gastrointestinal side effects, particularly diarrhea, become common. Resveratrol usage may increase the risk of adverse effects of certain drugs. Source: Memorial Sloan Kettering Cancer Center

Other Conditions

What is not supported by current evidence: Taking resveratrol to slow aging, extend lifespan, or prevent cancer. The original sirtuin-activation hypothesis has not held up, the ITP found no lifespan benefit, and human cancer data is far too thin.

What has some clinical support, but remains preliminary: Modest improvements in glucose metabolism and insulin sensitivity (especially as an adjunct to diabetes treatment), some blood pressure reduction, and possible cardiovascular biomarker benefits. These findings are real but inconsistent across studies.

What we still do not know: Whether improved bioavailability formulations might change the picture; whether resveratrol’s metabolites (rather than the parent compound) are doing the heavy lifting in positive studies; and whether the gut microbiome explains why some people seem to respond to resveratrol and others do not.

Resveratrol remains a fascinating compound with genuine biological activity. But “fascinating” and “worth taking as a supplement” are not the same thing. If you are currently taking it for longevity purposes, the evidence suggests your money and attention would be better directed elsewhere. If you are taking it for metabolic health under medical guidance, the conversation is more nuanced — and worth having with your doctor.

The Bottom Line

Claim	Evidence Status
Anti-aging in humans	Not demonstrated; animal data doesn’t translate
Sirtuin SIRT1 activation in humans	Not reliably shown in randomized controlled trials (RCTs)
Cardiovascular/metabolic benefits	Modest positive signals in humans; not definitive
Anti-cancer (general)	Strong preclinical data; human trials inconclusive
Cancer-promoting risk (ER+ breast cancer)	Real concern, especially at high supplement doses
Estrogenic activity	Confirmed; context-dependent effects
Neuroprotective	Some promising early signals

The verdict

Barring further studies, the bulk of the evidence at this point suggests that:

Resveratrol is a biologically active compound with real effects — but those effects are bidirectional, dose-dependent, cell-type-dependent, and far more complicated than early headlines suggested.
The bioavailability problem alone makes it hard to take most cell culture data seriously as a guide to supplementation.
For people with hormone-sensitive cancers particularly, the estrogenic concern is not theoretical — it warrants real caution.
The field has largely moved on toward compounds with stronger and more consistent evidence.
For those interested in sirtuin pathway support, NMN, NR and NA (nicotinic acid) (NAD+ precursors) currently have more mechanistically coherent human data than resveratrol does.

What I’m doing

I took resveratrol for two years during the period when David Sinclair was heavily promoting it.
I’ve stopped doing so and have no plans to resume.
I view it as a bioactive compound which might someday turn out to have useful pharmacological effects.
I find its effects in re: type 2 diabetes to be interesting, but I do not regard it as an effective anti-aging supplement.

Bibliography

Rogina, B. & Tissenbaum, H.A. (2024). “SIRT1, resveratrol and aging.” Frontiers in Genetics, 15, 1393181. https://doi.org/10.3389/fgene.2024.1393181
Healthspan. “Resveratrol and Aging: A Comprehensive Review of Longevity Claims and Scientific Findings.” https://www.gethealthspan.com/research/article/resveratrol-aging-longevity-review
Memorial Sloan Kettering Cancer Center. “Resveratrol.” Integrative Medicine. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/resveratrol
Ren, Z-Q., Zheng, S-Y., Sun, Z., et al. (2025). “Resveratrol: Molecular Mechanisms, Health Benefits, and Potential Adverse Effects.” MedComm, 6(6), e70252. https://doi.org/10.1002/mco2.70252
Mansouri, F., Feliziani, G., Bordoni, L., & Gabbianelli, R. (2025). “Impact of Resveratrol Supplementation on Human Sirtuin 1: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.” Journal of the Academy of Nutrition and Dietetics, 125(9), 1299–1314. https://doi.org/10.1016/j.jand.2025.03.011
Yıldırım, T.D. (2024). “Resveratrol Therapeutic Potential in Age-Related Diseases.” Anti-Aging Eastern Europe, 3(4), 194–201. https://antiagingeeu.com/index.php/journal/article/download/107/92/
Sah, P., Rai, A.K., & Syiem, D. (2025). “Sirtuin activators as an anti-aging intervention for longevity.” Exploration of Drug Science, 3, 100881. https://www.explorationpub.com/uploads/Article/A100881/100881.pdf
Berman, A.Y., Motechin, R.A., Wiesenfeld, M.Y., & Holz, M.K. (2017). “The therapeutic potential of resveratrol: a review of clinical trials.” npj Precision Oncology, 1, 35. https://doi.org/10.1038/s41698-017-0038-6
Levi, F. et al. (2005). “Resveratrol and breast cancer risk.” European Journal of Cancer Prevention, 14(2), 139–142. https://pubmed.ncbi.nlm.nih.gov/15785317/
Poschner, S. et al. (2018). “Resveratrol Inhibits Key Steps of Steroid Metabolism in a Human Estrogen-Receptor Positive Breast Cancer Model.” Frontiers in Pharmacology. https://pmc.ncbi.nlm.nih.gov/articles/PMC6048268/
Andreani, C. et al. (2017). “Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor.” Aging (Albany NY), 9, 508–523. https://pmc.ncbi.nlm.nih.gov/articles/PMC5361678/
Singh, B. et al. (2014). “Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways.” Carcinogenesis, 35(8), 1872–1880. https://academic.oup.com/carcin/article/35/8/1872/319100
Chow, H-H.S. et al. (2014). “A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones.” Journal of Translational Medicine, 12, 223. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-014-0223-0

Donations welcome

Donations make this website possible.
To donate using Buymeacoffee, please click here.